Vyne Therapeutics

VYNEPhase 3

Bridgewater, United StatesFounded 2020vynetherapeutics.com

VYNE Therapeutics is a publicly-traded biotech company (NASDAQ: VYNE) that questions traditional assumptions to develop better solutions for challenging therapeutic areas, primarily in dermatology and inflammation. Its core technology is the InhiBET™ platform of bromodomain and extra-terminal (BET) inhibitors, with lead candidates VYN201 and VYN202. In a transformative move, VYNE has entered into a definitive merger agreement with Yarrow Bioscience, which will bring in a late-stage clinical asset (YB-101) and approximately $200 million in pre-closing financing, aiming to create a combined company with a diversified pipeline and extended cash runway into 2028.

Market Cap

$21.0M

Founded

2020

Focus

Small Molecules

AI Company Overview

Technology Platform

InhiBET™ BET Inhibitor Platform: A proprietary platform developing locally administered and oral bromodomain and extra-terminal (BET) protein inhibitors for the treatment of inflammatory and fibrotic diseases.

Pipeline Snapshot

36 drugs in pipeline, 9 in Phase 3

Drug	Indication	Stage
Isotretinoin + Amzeeq 4% Topical Foam	Acne Vulgaris	Approved
5 mg Serlopitant Tablets	Pruritus	Phase 3
5mg Serlopitant Tablets + Placebo Tablets	Pruritus	Phase 3
5mg Serlopitant Tablets + Placebo Tablets	Pruritus	Phase 3
FMX-101, 4% minocycline foam + Vehicle Foam	Acne Vulgaris	Phase 3

Opportunities

The merger with Yarrow provides immediate access to a late-stage, first-in-class antibody for large autoimmune endocrine markets (Graves' disease, Thyroid Eye Disease) and a $200M cash runway.

Success in the Phase 1b trial for VYN201 in vitiligo could validate the InhiBET platform and open up multiple other dermatology/inflammation indications.

Risk Factors

High risk associated with clinical development of both lead assets (VYN201 and YB-101).

Integration risks from the pending merger.

Intense competition in target indications from recently approved, highly effective therapies (e.g., Tepezza for TED, Opzelura for vitiligo).

Competitive Landscape

In Graves' Disease/TED, competes against standard anti-thyroid drugs, surgery, and biologics like Tepezza. In vitiligo, competes against the new standard of care, JAK inhibitors like Opzelura. Differentiation for YB-101 is its novel anti-TSHR mechanism; for VYN201, it's the novel BET inhibitor mechanism applied topically.